The effects of cell penetrating peptides structure modification on their siRNA delivery function in vitro and in vivo

Progress in Biochemistry and Biophysics

Volumn 39, Issue 5, 2012, Pages 402-409

  Zhang, Hong Jie ^a   James, Q Yin ^a,b   Yin, Qin Wei ^a,b  

^a INSTITUTE OF BIOPHYSICS   (China)

^b Beijing Military Genral Hospital   (China)

Author keywords

Cell penetrating peptides; Delivery system; Small rna; Structure modification; Therapeutic application

Indexed keywords

EID: 84865019576     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2012.00052     Document Type: Review

References (37)

1. Wang J Y, Cai R, Luo B Y. Prog Biochem Biophys, 2009, 36(1): 25-32
2. Chen W J, Yin G, Zhao G J, et al. Prog Biochem Biophys, 2011, 38(9): 781-790
3. Guo W R, Yin Q W. Prog Biochem Biophys, 2006,33(1): 10-16
4. Jiang L, Pan S J, Ge Y Z, et al. Prog Biochem Biophys, 2008, 35(12): 1394-1402
5. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta, 2011, 1816(2): 232-246
6. Schroeder J A, Bitler B G. Anti-cancer therapies that utilize cell penetrating peptides. Recent Pat Anticancer Drug Discov, 2010, 5(2): 1-10
7. King J E, Eugenin E A, Buckner C M, et al. HIV tat and neurotoxicity. Microbes Infect, 2006,8(5): 1347-1357 (Pubitemid 43842005)
8. Weeks B S, Lieberman D M, Johnson B, et al. Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC 12 cells requires the Tat amino acid 49-58 basic domain. J Neurosci Res, 1995, 42(1): 34-40
9. Sabatier J M, Vives E, Mabrouk K, et al. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol, 1991, 65(2): 961-967
10. Yi X, Zhao G, Zhang H J, et al. MITF-siRNA formulation is a safe and effective therapy for human melasma. Mol Ther, 2011, 19(2): 362-371
11. Akkarawongsa R, Cullinan A E, Zinkel A, et al. Corneal toxicity of cell-penetrating peptides that inhibit Herpes simplex virus entry. J Ocular Pharmacol Ther, 2006, 22(4): 279-289 (Pubitemid 44689668)
12. Park Y J, Chang L C, Liang J F, et al. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J, 2005, 19(11): 1555-1557 (Pubitemid 41279029)
13. Konate K, Crombez L, Deshayes S, et al., Insight into the cellular uptake mechanism of o secondary amphipathic cell-penetrating peptide for siRNA delivery. Biochemistry, 2010, 49(16): 3393-3402
14. Rydström A, Deshayes S, Konate K, et al. Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. PLoS ONE, 2011, 6(10):e25924.doi:10.1371/journal. pone.0025924
15. Ryu D W, Kim H A, Ryu J H, et al. Amphiphilic peptides with arginine and valine residues as siRNA carriers. J Cell Biochem, 2012,113(2): 619-628
16. =[16] Tanaka K, Kanazawa T, Ogawa T, et al. Disulfide crosslinked stearoyl carrier peptides containing arginine and histidine enhance siRNA uptake and gene silencing. Int J Pharm, 2010, 398(1-2): 219-224
17. Bartz R, Fan H, Zhang J, et al. Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape. Biochem J, 2011, 435(2): 475-487
18. Katayama S, Hirose H, Takayama K, et al. Acylation of octaarginine: Implication to the use of intracellular delivery vectors. J Control Release, 2011, 149(1): 29-35
19. Baoum A, Ovcharenko D, Berkland C. Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing. Int J Pharm. 2011, doi:10.1016/j.ijpharm.2011.08. 012
20. Won Y W, Yoon S M, Lee K M, et al. Poly(oligo-D-arginine) with internal disulfide linkages as a cytoplasm-sensitive carrier for siRNA delivery. MoI Ther, 2011, 19(2): 372-380
21. Eguchi A, Meade B R, Chang Y C, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol, 2009, 27(6): 567-571
22. Schwarze S R, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 1999, 285(5433): 1569-1572 (Pubitemid 29420581)
23. 123I-labeled HIV-I tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclindependent kinase inhibitor, p21 (WAF-1/Cip-l). Eur J Nucl Med Mol Imaging, 2007, 34(3): 368-377
24. Kumar P, Wu H, McBride J L, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature, 2007, 448(7149): 39-43 (Pubitemid 47037001)
25. Kim S S, Ye C, Kumar P, et al. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther, 2010, 18(5): 993-1001
26. Pulford B, Reim N, Bell A, et al. Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One, 2010, 5(6): e11085.doi:10.1371/journal. pone.0011085
27. Chen Y, Shen Y, Guo X, et al. Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol, 2006, 24(4): 455-460
28. Lin C M, Huang K, Zeng Y, et al. A simple, noninvasive and efficient method for transdermal delivery of siRNA. Arch Dermatol Res, 2011, DOI 10.1007/s00403-011-1181-5
29. Hsu T, Mitragotri S. Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer. Proc Natl Acad Sci USA, 2011, 108(38): 15816-15821
30. Song K H, Fasano A, Eddington N D. Effect of the six-mer synthetic peptide (AT 1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A. Int J Pharm, 2008, 351(1-2): 8-14 (Pubitemid 351193100)
31. Song K H, Fasano A, Eddington N D. Enhanced nasal absorption of hydrophilic markers after dosing with AT 1002, a tight junction modulator. Eur J Pharm Biopharm, 2008, 69(1): 231-237 (Pubitemid 351467172)
32. Uchida T, Kanazawa T, Kawai M, et al. Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002. J Pharmacol Exp Ther, 2011, 338(2): 443-450
33. Uchida T, Kanazawa T, Takashima Y, et al. Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002. Chem Pharm Bull (Tokyo), 2011, 59(2): 196-201
34. Crombez L, Morris M C, Heitz F, et al. A non-covalent peptidebased strategy for ex vivo and in vivo oligonucleotide delivery. Methods Mol Biol, 2011,764: 59-73
35. Hayashi Y, Yamauchi J, Khalil I A, et al. Cell penetrating peptidemediated systemic siRNA delivery to the liver. Int J Pharm, 2011, 419(1-2): 308-313
36. Cheng C J, Saltzman W M. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cellpenetrating peptides. Biomaterials, 2011, 32(26): 6194-6203
37. Zhang W, Song J, Zhang B, et al. Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells. Bioconjug Chem, 2011, 22(7): 1410-1415